Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Phase 3 Recruiting
1,210 enrolled
TroFuse-019
Phase 3 Recruiting
780 enrolled
SOHO-02
Phase 3 Recruiting
444 enrolled
DeLLphi-312
Phase 3 Recruiting
330 enrolled
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Phase 2/3 Recruiting
596 enrolled
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
Phase 3 Recruiting
304 enrolled
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
Phase 2/3 Recruiting
1,260 enrolled
CheckMate-1533
Phase 2 Recruiting
76 enrolled
Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50%
Phase 2 Recruiting
156 enrolled
LuCa-MERIT-1
Phase 1 Recruiting
320 enrolled
INTerpath-009
Phase 3 Recruiting
680 enrolled
SEZanne
Phase 2 Recruiting
180 enrolled
DL03
Phase 1 Recruiting
304 enrolled
Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer
Phase 2 Recruiting
42 enrolled
PALOMA-2
Phase 2 Recruiting
520 enrolled
Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).
Phase 1 Recruiting
500 enrolled
eVOLVE-01
Phase 2 Recruiting
180 enrolled
Krascendo 2
Phase 3 Recruiting
600 enrolled
KANDLELIT-007
Phase 3 Recruiting
675 enrolled
INTerpath-13
Phase 2 Recruiting
180 enrolled
MK-6070-003
Phase 1/2 Recruiting
170 enrolled
A Phase II Clinical Study of FH-006 for Injection Combined With Other Anticancer Therapies in Subjects With Lung Cancer
Phase 2 Recruiting
200 enrolled
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Phase 1 Recruiting
1,006 enrolled
RAINFOL-01
Phase 1/2 Recruiting
764 enrolled
Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer
Phase 3 Recruiting
1,100 enrolled
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Phase 3 Recruiting
630 enrolled
MountainTAP-29
Phase 2/3 Recruiting
590 enrolled
REZILIENT4
Phase 3 Recruiting
360 enrolled
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
Phase 3 Recruiting
474 enrolled
Safety and Efficacy Evaluation of Serplulimab Plus Chemo in SCLC Transformed From EGFR-mutated NSCLC After Treatment
Phase 2 Recruiting
36 enrolled
A Study of ZL-1310 in Subjects With Small Cell Lung Cancer
Phase 1 Recruiting
339 enrolled
A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
Phase 3 Recruiting
530 enrolled
IMMUNOLIFE2
Phase 2 Recruiting
162 enrolled
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Phase 1/2 Recruiting
295 enrolled
Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors
Phase 1/2 Recruiting
434 enrolled
eVOLVE-Meso
Phase 3 Recruiting
825 enrolled
MK-2870-009
Phase 3 Recruiting
520 enrolled
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
Phase 3 Recruiting
851 enrolled
Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC
Phase 2 Recruiting
318 enrolled
SKB500 Combinations in Patients With Small Cell Lung Cancer
Phase 2 Recruiting
80 enrolled
A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
Phase 1/2 Recruiting
428 enrolled
RELATIVITY1093
Phase 3 Recruiting
1,000 enrolled
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Phase 3 Recruiting
880 enrolled
MK-3475-01E
Phase 2 Recruiting
60 enrolled
Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC
Phase 1 Recruiting
288 enrolled
ALTAIR
Phase 1/2 Recruiting
152 enrolled
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
Phase 1/2 Recruiting
370 enrolled
Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients
Recruiting
538 enrolled
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
Phase 1 Recruiting
340 enrolled
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC
Phase 3 Recruiting
878 enrolled